Source: Avicanna Inc.
  • Avicanna (AVCN) has been chosen by Shoppers Drug Mart as its partner to transition its Medical Cannabis by Shoppers business
  • Avicanna will introduce MyMedi.ca, a new medical cannabis care platform.
  • MyMedi.ca will provide a collection of formulas of products in collaboration with Canadian licensed producers, and comprehensive training programs for the medical community
  • Avicanna Inc. (AVCN) opened trading at C$0.38 per share

Avicanna (AVCN) has been chosen by Shoppers Drug Mart as its partner to transition its Medical Cannabis by Shoppers business.

Medical Cannabis by Shoppers provides patients access to medical cannabis products from more than 30 licensed cannabis brands. Avicanna will introduce MyMedi.ca, a new medical cannabis care platform.

MyMedi.ca will provide a collection of formulas of products in collaboration with Canadian licensed producers, and comprehensive training programs for the medical community.

Shoppers Drug Mart’s President, Jeff Leger stated that he and his team are confident they have found the right partner in Avicanna to continue to support them.

“As we move away from medical cannabis distribution, we remain firm in our belief that this medication should be dispensed in pharmacies like all others and will continue our advocacy to that end.”

It is anticipated that the transfer will take place over the next three months.

Avicanna is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments.

Avicanna Inc. (AVCN) opened trading at C$0.38 per share.

More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.